Suresh K. Agarwal, Ph.D.
Affiliations: | 2014 | Experimental and Clinical Pharmacology | University of Minnesota, Twin Cities, Minneapolis, MN |
Area:
Pharmacology, PharmacyGoogle:
"Suresh Agarwal"Parents
Sign in to add mentor| Richard C. Brundage | grad student | 2014 | UMN | |
| (Clinical pharmacology and pharmacometric analyses of CNS drugs used in the acute management of seizures and spasticity.) | ||||
BETA: Related publications
See more...
Publications
|
You can help our author matching system! If you notice any publications incorrectly attributed to this author, please sign in and mark matches as correct or incorrect. |
| Kurumaddali A, Salem AH, Agarwal SK. (2019) A Meta-Analysis of Higher-risk Myelodysplastic Syndrome Trials to Evaluate the Relationship between Short-term Endpoints and Overall Survival. Journal of Cancer. 10: 5427-5433 |
| Agarwal S, Gopalakrishnan S, Mensing S, et al. (2019) Optimizing Venetoclax Dose in Combination with Low Intensive Therapies in Elderly Patients with Newly Diagnosed Acute Myeloid Leukemia: An Exposure-Response Analysis. Hematological Oncology |
| Salem AH, Dave N, Marbury T, et al. (2019) Pharmacokinetics of the BCL-2 Inhibitor Venetoclax in Subjects with Hepatic Impairment. Clinical Pharmacokinetics |
| Wei AH, Strickland SA, Hou JZ, et al. (2019) Venetoclax Combined With Low-Dose Cytarabine for Previously Untreated Patients With Acute Myeloid Leukemia: Results From a Phase Ib/II Study. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. JCO1801600 |
| Agarwal SK, Tong B, Bueno OF, et al. (2018) Effect of Azithromycin on Venetoclax Pharmacokinetics in Healthy Volunteers: Implications for Dosing Venetoclax with P-gp Inhibitors. Advances in Therapy |
| Lee JS, Roberts A, Juarez D, et al. (2018) Statins enhance efficacy of venetoclax in blood cancers. Science Translational Medicine. 10 |
| Cheung TT, Salem AH, Menon RM, et al. (2017) Pharmacokinetics of the BCL-2 Inhibitor Venetoclax in Healthy Chinese Subjects. Clinical Pharmacology in Drug Development |
| Kumar S, Kaufman JL, Gasparetto C, et al. (2017) Efficacy of venetoclax as targeted therapy for relapsed/refractory t(11;14) multiple myeloma. Blood |
| Agarwal SK, Mangal N, Menon RM, et al. (2017) Response Rates as Predictors of Overall Survival: A Meta-Analysis of Acute Myeloid Leukemia Trials. Journal of Cancer. 8: 1562-1567 |
| Salem AH, Dunbar M, Agarwal SK. (2017) Pharmacokinetics of venetoclax in patients with 17p deletion chronic lymphocytic leukemia. Anti-Cancer Drugs |